FCMI
AERI

Foresite Capital Management IV’s Aerie Pharmaceuticals AERI Stock Holding History

Foresite Capital Management IV’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100,500
Closed -$1.93M – 18
2019
Q3 		$1.93M Hold
100,500
– – 0.62% 19
2019
Q2 		$2.97M Buy
+100,500
New +$3.87M 0.84% 20

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Foresite Capital Management IV's AERI Position: Q2 2020 in Review

Foresite Capital Management IV sold out of Aerie Pharmaceuticals (AERI) in Q2 2020, closing a stake of 227,717 shares — an estimated $3.07M sold.

Foresite Capital Management IV first reported a position in AERI in Q4 2018 and held it in 6 quarters. The position peaked at $36.3M in Q4 2019. 155 funds tracked by Wall St. Rank hold AERI as of Q2 2020.

  • Foresite Capital Management IV reported no remaining Aerie Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Foresite Capital Management IV sold 227,717 Aerie Pharmaceuticals shares in Q2 2020, an estimated $3.07M.
  • Foresite Capital Management IV first reported a position in Aerie Pharmaceuticals in Q4 2018 and held it in 6 quarters.
  • Foresite Capital Management IV's Aerie Pharmaceuticals position peaked at $36.3M in Q4 2019.
  • 155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2020.

Based on Foresite Capital Management IV's 13F filing for Q2 2020, filed 13 Aug 2020.